BEIGF BeOne Medicines Ltd. — earnings, filings & institutional moves

Price chart

Daily historical data with per-account defaults

Latest close

$21.95

Period return

-3.35 (-13.24%)

Volume

2026-07-20O $21.95 H $21.95 L $21.95 C $21.95MA5 $21.95MA20 $21.95MA60 $22.24MA120 $23.19

6M · 123 barsYahoo Finance · USD2026-01-22 → 2026-07-20

Recent event timeline

Filings, earnings, research, and institutional changes — newest first

View all →

2026. 08. 05.Highin 15 days
다음 실적 발표 예정
예정된 실적 발표입니다. 일정과 시장 기대치를 확인하세요.
2025. 03. 31.Mediumlast year
2026년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2024. 09. 30.Medium2 years ago
2025년 3분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2024. 06. 30.Medium2 years ago
2025년 2분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2024. 03. 31.Medium2 years ago
2025년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2023. 09. 30.Medium3 years ago
2024년 3분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2023. 06. 30.Medium3 years ago
2024년 2분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2023. 03. 31.Medium3 years ago
2024년 1분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2022. 09. 30.Medium4 years ago
2023년 3분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.
2022. 06. 30.Medium4 years ago
2023년 2분기 실적 발표
실적이 발표되었습니다. 세부 수치와 가이던스는 원문에서 확인하세요.

Recent earnings

Consensus vs. actual, and revenue trend

Earnings tab →

Research actions

Rating & price-target changes

Research tab →

AI Brief (Premium)

Automated summary from public sources · not investment advice

Brief tab →

No AI brief generated yet. You can create one from the Brief tab.

Top institutions (13F)

Ranked by position value

Institutions tab →

Company info

BeOne Medicines AG, an oncology company, engages in discovering and developing various treatments for cancer patients in the United States, China, Europe, and internationally. The company's commercial stage products include BRUKINSA, a small molecule inhibitor of Bruton's Tyrosine Kinase (BTK) for the treatment of various blood cancers; TEVIMBRA, an anti-PD-1 antibody immunotherapy for the treatment of various solid tumor and blood cancers; SYLVANT for the treatment of adult patients with multicentric castleman disease; BAITUOWEI for patients with BC in premenopausal and perimenopausal women, and cancer; and PARTRUVIX for the treatment of various solid tumors. Its clinical stage products comprise Sonrotoclax BGB-11417, a small molecule Bcl-2 inhibitor; BGB-16673, a BTK targeting chimeric degradation activation compound active against wild type and mutant BTK; BG-60366, an EGFR-targeted CDAC; BG-89894 (SYH2039), a MAT2A Inhibitor; BGB-58067, an MTA-Cooperative PRMT5 Inhibitor; BG-T187 and BG-C0902, an anti-EGFRxMET trispecific antibody; BGB-26808, a HPK-1 Inhibitor; BGB-C354, an anti-B7H3 ADC; Zanidatamab, a bispecific HER2-targeted antibody; BG-C137, an anti-FGFR2b ADC; BGB-53038, a Pan-KRAS Inhibitor; BGB-B2033, an anti-GPC3x4-1BB bispecific antibody; BGB-B3227, an anti-MUC1xCD16A bispecific antibody; BG-C477, an anti-CEAADC; BGB-43395, a CDK4 Inhibitor; BG-68501, a CDK2 Inhibitor; BG-C9074, an anti-B7H4 ADC; BGB-21447, a Bcl-2 Inhibitor; and BGB-45035, an IRAK4-targeted CDAC. It also has various preclinical programs. The company has agreements Amgen, BMS, Bio-Thera, EUSA Pharma, Luye Pharmaceutical, and Novartis. The company was formerly known as BeiGene, Ltd. and changed its name to BeOne Medicines AG in May 2025. BeOne Medicines AG was founded in 2010 and is based in Basel, Switzerland.

Quarter	Date	Time	EPS est.	EPS actual	Surprise	Rev. est.	Rev. actual	Status
—	2026. 08. 05.	After market close (AMC)	—	—	—	$1.59B	—	Scheduled
FY2026 Q1	2025. 03. 31.	Time TBD	—	$0	—	—	$1.12B	Reported
FY2025 Q3	2024. 09. 30.	Time TBD	—	$-0.36	—	—	$2.68B	Reported
FY2025 Q2	2024. 06. 30.	Time TBD	—	$-0.27	—	—	$1.68B	Reported

BeOne Medicines Ltd.

Price chart

Recent event timeline

Recent earnings

Research actions

Top news

Key stats